These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7318328)

  • 1. Central dopaminergic mechanisms in young patients with essential hypertension.
    Kolloch RE; Stumpe KO; Ismer U; Kletzky O; Dequattro V
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():231s-234s. PubMed ID: 7318328
    [No Abstract]   [Full Text] [Related]  

  • 2. Central dopaminergic control of prolactin in essential hypertension.
    Os I; Kjeldsen SE; Westheim A; Normann N; Aakesson I; Hjermann I; Eide I
    Acta Med Scand Suppl; 1986; 714():113-7. PubMed ID: 3472433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension.
    Sowers JR; Nyby M; Jasberg K
    Hypertension; 1982; 4(3):431-7. PubMed ID: 7068198
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control.
    Stumpe KO; Kolloch R; Higuchi M; Krück F; Vetter H
    Lancet; 1977 Jul; 2(8031):211-4. PubMed ID: 69827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic modulation of pressor and hormonal responses in essential hypertension.
    Sowers JR; Golub MS; Berger ME; Whitfield LA
    Hypertension; 1982; 4(3):424-30. PubMed ID: 6279498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased central dopaminergic activity in essential hypertension.
    Os I; Kjeldsen SE; Westheim A; Aakesson I; Norman N; Enger E; Hjermann I; Eide I
    J Hypertens; 1987 Apr; 5(2):191-7. PubMed ID: 3611768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Excessive prolactinemic response to sulpiride in patients with mild essential hypertension. Index of diminished hypothalamic dopaminergic activity].
    Paladini G; Sponza E; Geatti O; Di Chiara F; Bertolutti T
    Minerva Med; 1980 Sep; 71(31):2229-35. PubMed ID: 6999383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin, dopaminergic mechanisms and hypertension.
    Slater IH
    Clin Exp Hypertens A; 1983; 5(4):559-61. PubMed ID: 6851199
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminergic modulation of salt sensitivity in patients with essential hypertension.
    Shikuma R; Yoshimura M; Kambara S; Yamazaki H; Takashina R; Takahashi H; Takeda K; Ijichi H
    Life Sci; 1986 Mar; 38(10):915-21. PubMed ID: 3951317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenergic and dopaminergic regulation of circulating beta-endorphin-like immunoreactivity in hypertension.
    Alföldi A; Simkó K; Fekete MI; Farsang C
    Acta Physiol Hung; 1991; 78(1):99-106. PubMed ID: 1763654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lack of effect of aging on dopaminergic inhibition of aldosterone and prolactin increase].
    Preis P; Luger A; Templ H; Tragl HK; Geyer G
    Z Gerontol; 1985; 18(4):241-3. PubMed ID: 3901563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma prolactin, renin and catecholamines in young normotensive and borderline hypertensive subjects.
    Saito I; Takeshita E; Saruta T; Nagano S; Sekihara T
    J Hypertens; 1984 Feb; 2(1):61-4. PubMed ID: 6397523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dopamine in the development of spontaneous hypertension.
    van den Buuse M; Versteeg DH; de Jong W
    Hypertension; 1984; 6(6 Pt 1):899-905. PubMed ID: 6519747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic control of circadian norepinephrine levels in patients with essential hypertension.
    Sowers JR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1133-7. PubMed ID: 7298797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dopaminergic mechanisms on 24-hour secretory patterns of prolactin, luteinizing hormone and testosterone in recumbent men.
    Sowers JR; Viosca SP; Windsor C; Korenman SG
    J Endocrinol Invest; 1983 Feb; 6(1):9-15. PubMed ID: 6841919
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hemodynamic and biological effects of bromocriptine in essential hypertension].
    Allain H; Daubert JC; Massart C; van den Driessche J; Gouffault J
    Arch Mal Coeur Vaiss; 1982 Sep; 75(9):951-62. PubMed ID: 6816179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic mediation of beta-endorphin-induced prolactin secretion.
    Van Loon GR; De Souza EB; Shin SH
    Neuroendocrinology; 1980 Oct; 31(4):293-6. PubMed ID: 6252497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of the renal tubular dopaminergic activity by oral calcium supplementation in patients with essential hypertension.
    Dazai Y; Iwata T; Hiwada K
    Am J Hypertens; 1993 Nov; 6(11 Pt 1):933-7. PubMed ID: 8305167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study.
    da Silva Alves F; Schmitz N; Figee M; Abeling N; Hasler G; van der Meer J; Nederveen A; de Haan L; Linszen D; van Amelsvoort T
    J Psychopharmacol; 2011 Apr; 25(4):538-49. PubMed ID: 20530591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prolactin determination as a means of estimating the level of dopaminergic function during coma].
    Roquefeuil B; Blanchet P
    Agressologie; 1980; 21(4):225-31. PubMed ID: 7246908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.